More than half of American men over the age of 50 will be diagnosed with an enlarged prostate (benign prostatic hyperplasia) or BPH. Ausio Pharmaceuticals and The Urology Center of Colorado (TUCC) are now partnering in the investigation of a new treatment for BPH. The existing treatments for BPH include alpha adrenergic blockers which are effective for urinary symptoms but include difficult side effects such as sexual dysfunction, dizziness and headache. In addition, while the widely prescribed 5-a-reductase inhibitors are proven effective, but it may take several months for the advantages of those drugs to show results.
This groundbreaking new discovery for BPH is based on a process which occurs naturally in the body of some individuals. The new drug is the bi-product after soy protein is ingested and metabolized by the digestive system. The soy derivative can reduce the size of the prostate and improve bothersome urinary symptoms. In Asia, 80 percent of the population naturally produce the derivative. In contrast, fewer than 25 percent of North Americans and Europeans produce this beneficial derivative which has a powerful ability to down regulate the hormones that drive the progression of BPH.
“Because the number of American men diagnosed with BPH is increasing, it is absolutely critical that clinical research be conducted in order to improve quality of life of these patients, said Lawrence Karsh, M.D., TUCC Clinical Research Director and Principal Investigator of this new research. “We are pleased to have been selected as a national research site for this pivotal trial, offering patients in the Rocky Mountain region access to tomorrow’s therapies today.”
To learn more about this research, Dr. Karsh or programs at TUCC, visit www.tucc.com or call 303.783.2773 to speak with TUCC’s Clinical Research Coordinator.